Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6074090 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6074158 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL6285618 | 0.98 | SMN1; SMN2 (0.55) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL4584901 | 0.98 | SMN1; SMN2 (0.55) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| Oxalic Acid SCHEMBL29615378 | 0.91 | SMN1; SMN2 (0.53) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24919476 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28924921 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30065165 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28924924 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6372735 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0005848-B1 | N-ALKYLATED AMINOALCOHOLS AND THEIR SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1981-12-30 | — | — | EP | claimed |
| WO-2024098071-A1 | THERAPEUTIC REGIMENS AND METHODS FOR TREATMENT OF CARDIOVASCULAR RISK FACTORS USING A GLP-1R AND GCGR AGONIST | SPITFIRE PHARMA LLC (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240148879-A1 | GLP-1R, GIP-R AND/OR GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-05-09 | — | — | US | disclosed |
| CN-112601749-B | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment | 艾吉因生物股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2024059753-A2 | THERAPEUTIC REGIMENS AND METHODS FOR REDUCING BODY WEIGHT IN A SUBJECT WITH FATTY LIVER DISEASE USING A GLP-1R AND GCGR AGONIST | SPITFIRE PHARMA LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20240050459-A1 | Nicotinyl Riboside Compounds and Their Uses | MITOPOWER LLC | 2024-02-15 | — | — | US | disclosed |
| CN-117202924-A | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balance agonists | 斯皮特弗尔制药有限责任公司 | 2023-12-08 | — | — | CN | disclosed |
| US-11833167-B2 | Nicotinyl riboside compounds and their uses | MITOPOWER LLC (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4255564-A1 | THERAPEUTIC REGIMENS AND METHODS FOR LOWERING BLOOD GLUCOSE AND OR BODY WEIGHT USING GLP-1R AND GCGR BALANCED AGONISTS | Spitfire Pharma LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023168329-A2 | NOVEL PRODRUGS DERIVED FROM NICOTINIC ACID AND RIBOSE | MITOPOWER, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-5908830-A | COMBINATION OF A METABOLIC RATE MODIFYING AGENT (E.G., A BETA-3 ADRENERGIC RECEPTOR AGONIST) AND A FEEDING BEHAVIOR MODIFYING AGENT (E.G., A NPY5 ANTAGONIST) | MERCK & CO., INC. (US) | 1999-06-01 | — | — | US | disclosed |
| US-5256626-A | Herbicidal compositions safened by 5-heterocyclic-substituted oxazolidine dihaloacetamides compounds | MONSANTO COMPANY (US) | 1993-10-26 | — | — | US | disclosed |
| US-5225570-A | Plant safening agents for crops treated with herbicides | MONSANTO COMPANY (US) | 1993-07-06 | — | — | US | disclosed |
| EP-0304409-B1 | 5-HETEROCYCLIC-SUBSTITUTED OXAZOLIDINE HALOACETAMIDES | MONSANTO CO (US) | 1992-10-28 | — | — | EP | disclosed |
| US-5106986-A | PREPARATION OF AMINOETHANOL DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-04-21 | — | — | US | disclosed |
| EP-0450180-A2 | Process for the preparation of aminoethanol derivatives | BAYER AG (DE) | 1991-10-09 | — | — | EP | disclosed |
| EP-0428434-A2 | Compounds of aromatic amines and their enantiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1991-05-22 | — | — | EP | disclosed |
| EP-0304409-A1 | 5-Heterocyclic-substituted oxazolidine haloacetamides | MONSANTO COMPANY (US) | 1989-02-22 | — | — | EP | disclosed |
| US-4460580-A | N-Alkylated aminoalcohols and their pharmaceutical compositions useful for the treatment of cardiac insufficiency | CIBA-GEIGY CORPORATION (US) | 1984-07-17 | — | — | US | disclosed |
| EP-0005848-A1 | N-Alkylated aminoalcohols and their salts, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1979-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050459-A1 | Nicotinyl Riboside Compounds and Their Uses | NADK, NNT, NAMPT | SMN1; SMN2 191/4885CFTR 793/4885SLC6A2 835/4885 |
| US-20240148879-A1 | GLP-1R, GIP-R AND/OR GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE | GIPR, GLP1R, GCGR | SMN1; SMN2 2492/4885CFTR 319/4885SLC6A2 1371/4885 |
| US-11833167-B2 | Nicotinyl riboside compounds and their uses | NADK, NNT, NAMPT | SMN1; SMN2 191/4885CFTR 793/4885SLC6A2 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.